Primary surgery or neoadjuvant chemotherapy in ovarian cancer: What is the value of comparing apples with oranges?

Gynecologic Oncology

Volumn 124, Issue 1, 2012, Pages 1-2

  Vergote, Ignace ^a   Leunen, Karin ^a   Amant, Frédéric ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; PACLITAXEL;

ADJUVANT CHEMOTHERAPY; ADVANCED CANCER; CANCER MORTALITY; CANCER SURVIVAL; CYTOREDUCTIVE SURGERY; EDITORIAL; FISTULA; HUMAN; INTERMETHOD COMPARISON; META ANALYSIS (TOPIC); OVARY CANCER; OVERALL SURVIVAL; POSTOPERATIVE COMPLICATION; POSTOPERATIVE HEMORRHAGE; POSTOPERATIVE INFECTION; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SURGICAL MORTALITY; TREATMENT OUTCOME; VEIN DISEASE;

FALLOPIAN TUBE NEOPLASMS; FEMALE; HUMANS; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS;

EID: 83055169672     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2011.11.010     Document Type: Editorial

References (9)

1. D. Chi, F. Musa, and F. Dao An analysis of patients with bulky advanced stage ovarian, tubal and peritoneal carcinoma treated with primary debulking surgery (PDS) during an identical time period as the randomized EORTC-NCIC trial of primary debulking surgery vs neoadjuvant chemotherapy (NACT) Gynecol Oncol 124 2012 10 14
2. I. Vergote, C.G. Tropé, and F. Amant Neoadjuvant chemotherapy or primary surgery in Stage IIIc-IV ovarian cancer New Engl J Med 363 2010 943 953
3. I. Vergote, I. De Wever, W. Tjalma, M. Van Gramberen, J. Decloedt, and P. Van Dam Neoadjuvant chemotherapy or primary debulking surgery in advanced ovarian carcinoma: a retrospective analysis of 285 patients Gynecol Oncol 71 1998 431 436 (Pubitemid 29022333)
4. R.E. Bristow, and D.S. Chi Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: a meta-analysis Gynecol Oncol 103 2006 1070 1076 (Pubitemid 44821335)
5. S. Kang, and B.H. Nam Does neoadjuvant chemotherapy increase optimal cytoreduction rate in advanced ovarian cancer? Meta-analysis of 21 studies Ann Surg Oncol 16 2009 2315 2320
6. I. Vergote, C.G. Tropé, F. Amant, T. Ehlen, N.S. Reed, and A. Casado Neoadjuvant chemotherapy is the better treatment option in some patients with stage IIIc to IV ovarian cancer J Clin Oncol 29 2011 4076 4078
7. T. Onda Patients with ovarian carcinoma upstaged to stage III after systematic lymphadenectomy have similar survival to Stage I/II patients and superior survival to other Stage III patients Cancer 83 1998 1555 1560 (Pubitemid 28465473)
8. G.C. Stuart, H. Kitchener, M. Bacon, A. du Bois, M. Friedlander, J. Ledermann, C. Marth, T. Thigpen, E. Trimble The participants of 4th Ovarian Cancer Consensus Conference (OCCC) of the Gynecologic Cancer Intergroup 2010 Gynecologic Cancer InterGroup (GCIG) consensus statement on clinical trials in ovarian cancer: report from the Fourth Ovarian Cancer Consensus Conference Int J Gynecol Cancer 21 2011 750 755
9. I. Vergote, F. Amant, G. Kristensen, T. Ehlen, S.N. Reed, and A. Casado Primary surgery or neoadjuvant chemotherapy followed by interval debulking surgery in advanced ovarian cancer Eur J Cancer 47 Suppl. 3 2011 S88 S92